Breast Cancer Clinical Trial
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Summary
The objective of this study was to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy
Eligibility Criteria
Inclusion Criteria:
Documentation of histological or cytological confirmation of estrogen receptor positive (ER+) and HER2 negative adenocarcinoma of the breast must be available.
Women (≥18 years of age) with metastatic breast cancer not amenable to curative treatment by surgery or radiotherapy.
Documentation of menopausal status: post menopausal or premenopausal subjects are eligible.
Subjects with bone dominant disease with at least 2 skeletal metastases identified at baseline by bone scintigraphy and confirmed by CT/magnetic resonance imaging (MRI). Presence of metastases in soft tissue (skin, subcutaneous, muscle, fat, lymph nodes)and/or visceral metastases is allowed.
Measurable or non-measurable disease (but radiologically evaluable) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
Subjects must have received at least one line of hormonal therapy in the metastatic setting
Subjects who are eligible for further standard of care endocrine treatment.
Subjects enrolled in the current study must start treatment with the single hormone agent either within 15 days prior to randomization or after randomization (before or simultaneously to the first injection of Ra-223/placebo).
Subjects must have experienced no more than two skeletal-related events (SREs) prior to study entry defined as: Need for external beam radiotherapy (EBRT) tor bone, pathological bone fracture (excluding major trauma), spinal cord compression and/or orthopedic surgical procedure. Subjects with no prior SREs are not permitted.
Subjects must be on therapy with bisphosphonate and denosumab. and are required to have been on such therapy for at least 1 month before start of study treatment.
Adequate hematological, liver and kidney function.
Exclusion Criteria:
Subjects with Inflammatory breast cancer.
Subjects who have either received chemotherapy for metastatic disease or are considered by the treating investigator to be appropriate candidates for chemotherapy as current treatment for metastatic breast cancer are excluded. Chemotherapy administered for adjuvant/neo adjuvant disease is acceptable.
Subjects with known or history of brain metastases or leptomeningeal disease: subjects with neurological symptoms must undergo a contrast CT scan or MRI of the brain within 28 days prior to randomization to exclude active brain metastasis. Imaging of the central nervous system (CNS) is otherwise not required.
Known presence of osteonecrosis of jaw.
Patients with immediately life-threatening visceral disease, for whom chemotherapy is the preferred treatment option.
Lymphangitic carcinomatosis.
Patients with ascites requiring paracentesis within 2 weeks prior to study entry (signature of informed consent) and during the screening period.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 68 Locations for this study
Bakersfield California, 93309, United States
La Jolla California, 92093, United States
Aurora Colorado, 80045, United States
New Haven Connecticut, 06520, United States
Cedar Rapids Iowa, 52403, United States
Annapolis Maryland, 21401, United States
Ann Arbor Michigan, 48109, United States
Pontiac Michigan, 48341, United States
Saint Louis Missouri, 63110, United States
Pittsburgh Pennsylvania, 15213, United States
Houston Texas, 77230, United States
Linz Oberösterreich, 4020, Austria
Innsbruck , 6020, Austria
Winnipeg Manitoba, R3E 0, Canada
London Ontario, N6A 4, Canada
Newmarket Ontario, L3Y 2, Canada
Toronto Ontario, M5G 2, Canada
Ostrava , 708 5, Czechia
Praha 2 , 12808, Czechia
Copenhagen , 2100, Denmark
Herlev , 2730, Denmark
Helsinki , 00290, Finland
Tampere , FIN-3, Finland
Angers Cedex , 49055, France
Saint Cloud , 92210, France
Tübingen Baden-Württemberg, 72076, Germany
Bonn Nordrhein-Westfalen, 53105, Germany
Essen Nordrhein-Westfalen, 45147, Germany
Kowloon , , Hong Kong
Cork , , Ireland
Dublin , 7, Ireland
Afula , 18341, Israel
Haifa , 31096, Israel
Jerusalem , 91031, Israel
Jerusalem , 91120, Israel
Kfar Saba , 44281, Israel
Ramat Gan , 52620, Israel
Tel Aviv , 64239, Israel
Zerifin , 70300, Israel
Busan , 49241, Korea, Republic of
Daegu , 42601, Korea, Republic of
Incheon , , Korea, Republic of
Seoul , 03080, Korea, Republic of
Seoul , 05505, Korea, Republic of
Seoul , 120-7, Korea, Republic of
Nieuwegein , 3435 , Netherlands
Zwolle , 8025 , Netherlands
Oslo , 0424, Norway
Bialystok , 15-02, Poland
Gdynia , 81-51, Poland
Warszawa , 02-78, Poland
Singapore , 11907, Singapore
L'Hospitalet de Llobregat Barcelona, 08907, Spain
A Coruña , 15009, Spain
Barcelona , 08025, Spain
Barcelona , 08036, Spain
Madrid , 28033, Spain
Madrid , 28040, Spain
Madrid , 28041, Spain
Málaga , 29010, Spain
Sevilla , 41071, Spain
Zaragoza , 50009, Spain
Aarau Aargau, 5001, Switzerland
Taipei , 11217, Taiwan
Plymouth Devon, PL6 8, United Kingdom
Northwood Middlesex, HA6 2, United Kingdom
Nottingham Nottinghamshire, NG5 1, United Kingdom
Taunton Somerset, TA1 5, United Kingdom
Cottingham , HU16 , United Kingdom
Merseyside , CH63 , United Kingdom
Sheffield , S10 2, United Kingdom
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.